HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir

HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir Key takeaways Powered by Yahoo Scout. Yahoo is using AI to generate key points from this article. This means the info may not always match what’s in the article. Reporting mistakes helps us improve the experience. NICE has recommended against reimbursing Gilead’s twice-a-year PrEP medication lenacapavir, prompting a rebuttal from HIV charities in the UK. The evaluation committee at NICE stated that lenacapavir should not be used as a PrEP option alongside safer sex practices to reduce the risk of HIV in high-risk adults and young people, leading to a draft recommendation that the drug should not be funded or used routinely in the NHS in England.